Safety and Efficacy of TOP1630 for Dry Eye Syndrome

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 20, 2017

Primary Completion Date

June 15, 2017

Study Completion Date

June 15, 2017

Conditions

Dry Eye Syndrome

Interventions

DRUG

TOP1630 Ophthalmic Solution

Bilateral ocular drug administration

DRUG

Placebo to TOP1630 Ophthalmic Solution

Bilateral ocular drug administration

Trial Locations (1)

Andover Eye Associates, Andover

All Listed Sponsors

collaborator

Topivert Pharma Ltd

INDUSTRY

lead

ORA, Inc.

INDUSTRY

NCT03088605 - Safety and Efficacy of TOP1630 for Dry Eye Syndrome | Biotech Hunter | Biotech Hunter